TOKYO, January 28, 2025 /PRNewswire/ — ThinkCyte, a biotechnology company pioneering artificial intelligence (AI)-based cell sorting and analysis instruments, today announced that it will begin pre-commercial launch of its new cellular analysis platform, VisionCyte™. The announcement coincides with the Society for Laboratory Automation and Screening (SLAS) 2025 Conference in San Diego, California Since January 27-30, 2025where VisionCyte was named a finalist for the 2025 New Product Award. The launch of VisionCyte expands ThinkCyte’s portfolio of life sciences research platforms beyond VisionSort, the company’s flagship product launching in 2023 and adopted by leading biopharmaceutical companies and academic institutions around the world.
The VisionCyte platform leverages high-resolution morphological profiling, high-throughput capabilities, and advanced AI analytics to discover novel biomarkers and facilitate the discovery of novel and diverse drug discovery hits and targets. Full commercial deployment of VisionCyte will occur in 2025, with an initial range of ready-to-use units available in the second half of 2025. The company also announced the launch of its Cellumate cell tracking kits, compatible with both VisionSort and VisionCyte, to enable discovery applications in areas where existing cellular markers on cell surfaces are limited, such as in specific hematological conditions, stem cell research and disease age-related.
“The expansion of our product portfolio reflects our unwavering commitment to advancing life sciences research. said Waichiro Katsuda, CEO of ThinkCyte. “By introducing innovative solutions that meet the evolving needs of scientists around the world, we don’t just add products: we provide the tools needed to accelerate discoveries in understanding diseases and drug discovery to improve the life.
For more information on the VisionCyte platform, visit the ThinkCyte booth (#2632) at SLAS 2025 or by visiting thinkcyte.com/visioncyte.
About ThinkCyte
ThinkCyte, founded in 2016 with offices in Tokyo, Japan And Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated and multidisciplinary technologies to enable research, diagnosis and therapeutic development in life sciences. The company pioneered Ghost Cytometry™, a proprietary, label-free, AI-based analysis and cell sorting technology, and partners with leading global biopharmaceutical companies and leading academic research institutions to conduct pioneering research. For more information, please visit www.thinkcyte.com.
Show original content:https://www.prnewswire.com/apac/news-releases/thinkcyte-expands-product-portfolio-to-drive-innovation-in-drug-discovery-and-disease-research-302360372.html
SOURCEThinkCyte Inc.
